Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that its holding, ReceptoPharm, has been invited to be a featured speaker at the 11th Annual Immunobiology Symposium in Tahoe City, California.
“It is an honor to have the opportunity to speak at this Symposium,” commented Dr. Paul Reid, CEO of ReceptoPharm, Inc. “We are planning to discuss our research and findings on the treatment of Multiple Sclerosis (MS) using our lead drug candidate, RPI-78M,” he added.
In 2005, ReceptoPharm completed a study of RPI-78M in an animal model of Multiple Sclerosis. EAE (experimental allergic encephalomyelitis) is the standard benchmark animal methodology for the study of MS. ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease.
“This Symposium will be a perfect opportunity for ReceptoPharm to highlight their findings and discuss their upcoming clinical trials,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “ReceptoPharm is preparing to begin their Phase IIb human clinical trial for Adrenomyeloneuropathy (AMN) and they are currently working with the FDA to seek approval to begin their Phase II human clinical trial for MS,” he concluded.
There has been a great deal of interest surrounding research in Multiple Sclerosis therapies. Currently there are five drugs prescribed for the treatment of the disease, representing a market of more than $2 billion. The most recently available drug, Tysabri, was voluntarily pulled from the marketplace in February 2005 by the drug's manufacturers, Biogen-Idec and Elan. It was later allowed to return to the market, but is now required to display a “black box” warning.
The 11th Annual Immunobiology Symposium is sponsored and coordinated by the Baylor College of Medicine and will take place from September 20-24, 2006. Other featured speakers include researchers from the National Institute of Health, Allergan, Los Alamos National Laboratory, the University of British Columbia, and the University of California.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The presentation at the Immunobiology Conference should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.